Carlo Carraro, Maria Grazia Piccioni, Anna Maria Zicari, Francesca Olivero, Caterina Anania, Viviana Matys, Simona Marra, Daniela De Canditiis, Anna Giugliano
Journal: Nutrients 2025;17(4):
PMID: 40005000
BACKGROUND
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by the appearance of recurrent eczematous lesions and intense itching. The World Allergy Organization (WAO) suggested the administration of probiotics in pregnant women at high risk of allergies in their children.
OBJECTIVES
Our study aims to evaluate the role of administering the strain PRL2010 during pregnancy and breastfeeding in preventing and/or reducing the severity of AD manifestations in children.
METHODS
It is a monocentric, randomized, double-blind, placebo-controlled trial with probiotic/placebo administration since the 36th week of gestation to mothers with atopy or a family history of atopy; the effects were evaluated over the first 12 months of the children's lives.
RESULTS
No severe adverse effects due to probiotic intake were reported in our cohort. Although proportionally fewer children with AD were in the probiotic group, the statistical analysis showed no significant differences between the probiotic and placebo groups. However, infants who developed the most severe forms of AD in the probiotic group showed a better clinical course during follow-up compared to those in the placebo group.
CONCLUSIONS
In conclusion, administering the probiotic strain PRL2010 during pregnancy and breastfeeding is safe and potentially beneficial; further large-scale studies may confirm its usefulness in improving the clinical manifestation of AD in children with a family history of atopy.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.